(Q35200997)

7 August 2017

1 reference

title

Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes (English)

1 reference

7 August 2017

3

Zbigniew Herman

1 reference

7 August 2017

1

Robert Krysiak

1 reference

7 August 2017

2

Boguslaw Okopień

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

63

1 reference

7 August 2017

issue

17

1 reference

7 August 2017

page(s)

1821-1854

1 reference

Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches

7 August 2017

cites work

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes

1 reference

12 December 2020

Testing for endothelial dysfunction

1 reference

12 December 2020

Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.

1 reference

12 December 2020

Are there potential non-lipid-lowering uses of statins?

1 reference

12 December 2020

The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells

1 reference

12 December 2020

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion

1 reference

12 December 2020

Effect of lovastatin on hemorheology in type II hyperlipoproteinemia

1 reference

12 December 2020

Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia

1 reference

12 December 2020

Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor--I in human endothelial cell cultures

1 reference

12 December 2020

Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages

1 reference

12 December 2020

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

1 reference

12 December 2020

Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents

1 reference

12 December 2020

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

1 reference

12 December 2020

Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease

1 reference

12 December 2020

Effect of atorvastatin on plasma fibrinogen

1 reference

12 December 2020

Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients

1 reference

12 December 2020

Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells

1 reference

12 December 2020

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

1 reference

12 December 2020

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

1 reference

12 December 2020

Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease

1 reference

12 December 2020

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs

1 reference

12 December 2020

Do HMG-CoA reductase inhibitors affect fibrinogen?

1 reference

12 December 2020

Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

12 December 2020

Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease

1 reference

12 December 2020

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

1 reference

12 December 2020

Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II Hyperlipoproteinemia

1 reference

12 December 2020

Statin drugs and dietary isoprenoids as antithrombotic agents.

1 reference

12 December 2020

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia

1 reference

12 December 2020

Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect

1 reference

12 December 2020

Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients

1 reference

12 December 2020

Statins and fibrinogen

1 reference

12 December 2020

Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients

1 reference

12 December 2020

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

12 December 2020

Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.

1 reference

12 December 2020

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

1 reference

12 December 2020

Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia

1 reference

12 December 2020

Fibrinogen and cardiovascular risk.

1 reference

12 December 2020

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin

1 reference

12 December 2020

Effect of an estrogen/statin combination on biochemical markers of endothelial function in human coronary artery cell cultures

1 reference

12 December 2020

Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients

1 reference

12 December 2020

The physiological aspects of fibrinolysis

1 reference

12 December 2020

Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia

1 reference

12 December 2020

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1 reference

12 December 2020

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability

1 reference

12 December 2020

Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease

1 reference

12 December 2020

Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia

1 reference

12 December 2020

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

1 reference

12 December 2020

Diabetes mellitus: a hypercoagulable state

1 reference

12 December 2020

Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia

1 reference

12 December 2020

Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol

1 reference

12 December 2020

Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering

1 reference

12 December 2020

Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin.

1 reference

12 December 2020

Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction.

1 reference

12 December 2020

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

1 reference

12 December 2020

Fibrinogen as a risk factor for stroke and myocardial infarction

1 reference

12 December 2020

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

12 December 2020

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 reference

12 December 2020

Simvastain affects TAFI and thrombomodulin in CAPD patients.

1 reference

12 December 2020

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

1 reference

12 December 2020

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

12 December 2020

Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

1 reference

12 December 2020

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

1 reference

12 December 2020

Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin

1 reference

12 December 2020

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin

1 reference

12 December 2020

Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin

1 reference

12 December 2020

Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering

1 reference

12 December 2020

Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation

1 reference

12 December 2020

Murine guanylate-binding protein: incomplete geranylgeranyl isoprenoid modification of an interferon-gamma-inducible guanosine triphosphate-binding protein

1 reference

12 December 2020

The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling

1 reference

12 December 2020

The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications

1 reference

12 December 2020

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

1 reference

12 December 2020

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

12 December 2020

Atorvastatin improves endothelial function in renal-transplant recipients

1 reference

12 December 2020

Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects

1 reference

12 December 2020

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

1 reference

12 December 2020

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

1 reference

12 December 2020

Inhibition of tissue-factor-mediated thrombin generation by simvastatin

1 reference

12 December 2020

Changing concepts of atherogenesis

1 reference

12 December 2020

Prospective study of endogenous tissue plasminogen activator and risk of stroke

1 reference

12 December 2020

A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration

1 reference

12 December 2020

The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.

1 reference

12 December 2020

Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients

1 reference

12 December 2020

High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes

1 reference

12 December 2020

Hemostasis and atherosclerosis.

1 reference

12 December 2020

Classical risk factors and emerging elements in the risk profile for coronary artery disease

1 reference

12 December 2020

Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease

1 reference

12 December 2020

Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation

1 reference

12 December 2020

Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo

1 reference

12 December 2020

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

1 reference

12 December 2020

Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease

1 reference

12 December 2020

Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus

1 reference

12 December 2020

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

1 reference

12 December 2020

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

1 reference

12 December 2020

Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes

1 reference

12 December 2020

Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet

1 reference

12 December 2020

HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

1 reference

12 December 2020

Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in [...]

1 reference

12 December 2020

Platelet-dependent thrombin generation in patients with hyperlipidemia

1 reference

12 December 2020

Non-lipid-related effects of statins

1 reference

12 December 2020

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

12 December 2020

Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment

1 reference

12 December 2020

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

1 reference

12 December 2020

Effects of diet, drugs, and genes on plasma fibrinogen levels

1 reference

12 December 2020

Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells

1 reference

12 December 2020

Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

12 December 2020

Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels

1 reference

12 December 2020

The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

1 reference

12 December 2020

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

12 December 2020

Statins induce hypothrombotic states?

1 reference

12 December 2020

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

1 reference

12 December 2020

Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.

1 reference

12 December 2020

The effect of fluvastatin on plasma fibrinogen levels.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Comparative study of HMG-CoA reductase inhibitors on fibrinogen

1 reference

12 December 2020

Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

1 reference

12 December 2020

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

12 December 2020

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group

1 reference

12 December 2020

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.

1 reference

12 December 2020

PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.

1 reference

12 December 2020

Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.

1 reference

12 December 2020

Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide

1 reference

12 December 2020

Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components

1 reference

12 December 2020

Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study

1 reference

12 December 2020

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

1 reference

12 December 2020

Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy

1 reference

12 December 2020

More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Effects of HMG-CoA reductase inhibitor on hemostasis

1 reference

12 December 2020

Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.

1 reference

12 December 2020

Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.

1 reference

12 December 2020

Hemostatic risk factors for atherothrombotic disease: an epidemiologic view

1 reference

12 December 2020

Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)?

1 reference

12 December 2020

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

12 December 2020

Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study

1 reference

12 December 2020

Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology

1 reference

12 December 2020

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

1 reference

12 December 2020

Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.

1 reference

12 December 2020

10.2165/00003495-200363170-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1053664386

0 references

1 reference